Jiangsu Yahong Meditech Co., Ltd. Class A

As of June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A carries a market capitalization of 5.68B, placing it among publicly traded companies globally. Its enterprise value stands at 4.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jiangsu Yahong Meditech Co., Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A has 572.19M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 19.58, and the price-to-book ratio stands at 4.19.

These figures are as of June 30, 2026. The EV/Sales ratio of 16.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.82B versus a market cap of 5.68B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A maintains a current ratio of 6.45, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.21, indicating elevated leverage, while an interest coverage ratio of -62.61 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A posted a negative return on equity (ROE) of -29.88, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -24.18, reflecting losses generated across the asset base. The company generates approximately 606,169.77 in revenue per employee across its workforce of 470.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.93 indicates how many times Jiangsu Yahong Meditech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A recorded an income tax benefit of -367,667.21 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -500.68M and -484.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A's stock has gained approximately 17.82% over the past 52 weeks. The 50-day moving average sits at 12.82, while the 200-day moving average is 12.64.

Over the twelve months ended June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A generated 285.20M in revenue and converted that into -484.72M in net income, yielding earnings per share of -0.89. EBITDA reached -494.59M, while operating income came in at -511.79M.

As of June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A holds 1.18B in cash and equivalents against 349.61M in total debt, resulting in a net debt position of -55.69M. Total book value stands at 1.35B, with working capital of 1.33B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A posted a gross margin of 72.17, reflecting its pricing power and cost economics. The operating margin of -179.45 and net profit margin of -169.96 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.24 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -2.76, meaning Jiangsu Yahong Meditech Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Jiangsu Yahong Meditech Co., Ltd. Class A has an Altman Z-Score of 5.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.